A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers.
William Jeffery EdenfieldKi ChungMark O'RourkeElizabeth CullJulie MartinHeather BowersWesley SmithWilliam Larry GluckPublished in: The oncologist (2021)
This single-cohort basket trial demonstrated clinical activity from combined checkpoint blockade in 23 of the 36 evaluable patients. Patients with rare cancers, not eligible for immunotherapy via conventional clinical trial mechanisms, should be considered for this therapy through compassionate use, further clinical trials, and national registry programs.
Keyphrases
- clinical trial
- phase ii study
- open label
- phase ii
- phase iii
- end stage renal disease
- study protocol
- ejection fraction
- chronic kidney disease
- newly diagnosed
- public health
- prognostic factors
- dna damage
- cell cycle
- locally advanced
- squamous cell carcinoma
- randomized controlled trial
- oxidative stress
- mesenchymal stem cells
- bone marrow
- cell therapy
- placebo controlled
- rectal cancer
- childhood cancer